Esketamine in Treatment-Resistant Depression and Suicidal Ideation: A Systematic Review
Journal of Education Health and Sport November 29, 2025 Natalia Dudziak, Zuzanna Drozd, Bartosz Niemiec et al.
Background. Major depressive disorder affects 20% of the global population, with treatment-resistant depression in 10-30% of cases. Patients with acute suicidal ideation need immediate intervention, yet conventional antidepressants require weeks to work. Esketamine offers rapid symptom reduction through NMDA receptor antagonism. Aim. To systematically review current evidence on efficacy and...